Redoxis will be at BIO-Europe Spring in Milan from March 17-19!
Our COO Nina Woodworth, will be representing Redoxis AB, engaging in discussions on preclinical drug development for autoimmune and inflammatory diseases.
At Redoxis, we provide in vitro and in vivo efficacy studies to accelerate drug discovery for small molecules, biologics, cell & gene therapies, and mRNA-based treatments. Whether you’re developing the next breakthrough therapy or optimizing your pipeline, we’re here to support your preclinical journey.